WEINBERG MEDICAL PHYSICS, INC. — Department of Health and Human Services SBIR Phase II: 102

WEINBERG MEDICAL PHYSICS, INC. — SBIR Phase II award from Department of Health and Human Services.

Amount
$1,902,723
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase II
Topic
102
Solicitation
PA12-088
NAICS
Place of performance
MD
Period
2013-06-01 → 2017-05-31

Description

DESCRIPTION provided by applicant Contrast enhanced MRI has been proven to be a very sensitive modality for the early diagnosis of breast cancer in young women and or in women with radiographically dense breasts The American Cancer Society recommends that high risk women with lifetime risk greater than should receive annual breast MRI screening Depending on the practitioner and study characteristics MRI may have a high false positive rate with specificity reported as low as which can lead to many unnecessary procedures or even over treatment Positron emission mammography andquot PEMandquot the breast specific high resolution molecular imaging system originally invented by the PI of the submitted proposal has been demonstrated to have a high negative predictive value Integrating a PEM system into MRI for combined imaging is therefore likely to increase diagnostic accuracy Furthermore the recent commercialization of PET CT and PET MR clinical systems has led to wide acceptance in the oncology community for combined anatomic and molecular imaging The goal of this application is therefore to design and construct a PEM system that could be used in conjunction with an MRI scanner The developed PEM MRI system in this project could be used in cancer detection in personalizing care for breast cancer patients and in the development of new drugs for prevention and therapy PUBLIC HEALTH RELEVANCE The goal of this application is therefore to design and construct a molecular breast imaging system that could be used in conjunction with an MRI scanner The system could be used in breast cancer detection in personalizing care for breast cancer patients and in the development of new drugs for prevention and therapy